Article focus Levetiracetam (LEV) is a new and widely used Anti Epileptic Drug.
Results Forty nine percent of PWE on LEV and 39% on AED other than LEV reported anger as sometimes or always being a problem (p=0.042). Forty eight percent of PWE on LEV and 45% on AED other than LEV reported depression as sometimes or always being a problem (p=0.584). Seven percent of control subjects reported anger as sometimes being a problem, 93% reported anger as never or rarely being a problem.
Depression was never a problem in 75% of controls and rarely a problem in 25%.
Conclusions Anger and depression were more frequently reported as a problem by PWE than by control subjects. Our observational register of self-reported symptoms suggested anger being more often a problem in patients taking LEV than in PWE taking other AED.
PWE should be informed about this potential problem of LEV.
Keywords: Epilepsy, Levetiracetam, adverse effects. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (AED) compared to other AED in terms of rash risks, side effects on liver and kidney and drug interactions. Unfortunately, LEV can have psychiatric adverse effects including irritability, anger, agitation, aggressive behavior and depression. [1] [2] [3] [4] It has been estimated on the basis of collective evidence that 12-15% of all patients will suffer psychiatric side effects 1 but compared to our clinical experience this seemed low. Feelings of anger seemed to be a particular problem, but were often only reported on direct questioning because the patients were embarrassed. The aim of our study was to find out how many patients with epilepsy (PWE) on LEV were suffering from anger. Because doctors may under-report adverse effects 5 we obtained the information directly from the patients using a self-referral register.
Methods
The UK AED Register is a prospective register to study the efficacy and adverse effects of AED. The register was established at The Walton Centre for Neurology and Neurosurgery, Liverpool in July 2008. Anybody who takes AED can self-refer to the register. The register is independent from the pharmaceutical industry and has been Likert scale, with 1 indicating that there was never a problem; 2, rarely a problem; 3, sometimes a problem; and 4, always or often a problem. 6 The complete dataset is available on request.
We also collected age, gender, epileptic syndrome, severity of epilepsy, number of seizures in the last 4 weeks and other health problems, AED and other medication. We calculated the frequency of aggression occurring sometimes or always in patients on LEV and patients on other AED, and applied the chi squared test to test for associations of aggression with LEV. We did the same for the item depression.
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Results
Forty nine percent of patients on LEV and 39% on AED other than LEV reported anger as sometimes or always being a problem (p=0.042). Forty eight percent of patients on LEV and 45% on AED other than LEV reported depression as sometimes or always being a problem (p=0.584). In patients taking LEV <1000mg a day anger was reported as sometimes or always occurring in 43% and in patients taking LEV >1000mg a day in 52% (p=0.265). Anger occurred in LEV monotherapy in 48% and polytherapy in 50% (p=0.889). There was a trend for patients on LEV to be less likely to be seizure free than patients on other AED.
Seven percent of control subjects reported anger as sometimes being a problem, 93% reported anger as never or rarely being a problem. Depression was never a problem in 75% of controls and rarely a problem in 25%. The clinical characteristics of the patients are shown in tab.1.
Discussion
We found a small but statistically significant increase in self-reported anger in patients on LEV in mono and polytherapy compared to patients on other AED. About half of all patients on LEV reported anger as sometimes or always being a problem. Depression was not significantly associated with LEV. The regulatory trials suggested that LEV influenced affect. Symptoms including agitation, hostility, anxiety, apathy, emotional lability, depersonalisation and depression were reported in 13.3% of patients taking LEV and their standard AED medication compared to 6.2% of patients taking placebo and their standard AED medication. 7 Regulatory trials are not ideal for determination of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y behavioral adverse effects, as patients on antidepressants and major tranquillisers are often excluded from trials. LEV has been associated with anger. Many studies reported irritability, anger, agitation, aggressive behavior and depression in patients taking LEV [1] [2] [3] [4] 8 but the incidence of these adverse effects was considered to be relatively low at 12-15%. 1 In our study the prevalence of self-reported anger was much higher. There are a number of possible explanations; doctors may be unaware of relatively subtle mood changes, they may fail to report them or patients may be too embarrassed to spontaneously report anger. In a previous small study using the LAEP we also found a disturbingly high prevalence of self-reported adverse effects suggesting that the burden of taking AED is perhaps much higher than widely assumed by doctors. 9 This study also showed that even in monotherapy LEV was overall not better tolerated than older AED but had a different adverse effect profile. Feelings of anger were reported as always occurring in 33% of patients on LEV as opposed to 19% on Sodium Valproate, 16% on Carbamazepine and 15% Lamotrigine, in keeping with our current study [9] . That anger is a particular problem in LEV has been also suggested by a randomized prospective study comparing LEV with Lamotrigine (LTG). 10 LEV is a very unusual AED with a probable unique mode of action and is arguably one of the most effective new AED. LEV has a good adverse effect profile including low liver toxicity and lack of allergic skin reactions, there are no interactions with other drugs including the anti-contraceptive pill and LEV likely to have a low teratogenic risk. [11] [12] [13] LEV will remain an important AED and will potentially even become a first line drug at least in some epileptic syndromes such as juvenile myoclonic epilepsy in women. Having said this, it is important to advise patients with epilepsy about the potential of affective In our un-blinded observational study we could not exclude all confounding factors. The information came from the patients directly and not as in conventional custom via a physician. Our study therefore critically relied on the truthfulness of the patients. In addition, the median dose of some drugs such as Sodium Valproate, Lamotrigine, Topiramate and Zonisamide were higher in patients on LEV than in patients not on LEV.
There was also a trend for patients on LEV to be less likely seizure free (tab.1). LEV was used as second (or third) line drug in those patients with more difficult to control seizures. This was likely to have introduced bias and may have affected our findings.
Having said this, our data reflects current clinical practice. In the future when LEV is used as a first line drug an analysis with a large group of seizure free patients on LEV could clarify this issue.
It has to be kept in mind that we have selectively chosen to analyze LEV from our data pool. It is likely that analyzing other AED would also demonstrate problems in one or more areas covered by the LAEP. In addition, the risk of adverse effects has to be carefully balanced against the risk of seizures. Patients should be encouraged to take their medication. After all, half of all patients on LEV did not report anger. Nevertheless, patients with epilepsy should be made aware of this potential problem.
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Key messages
Forty nine percent of patients on LEV reported anger as being sometimes or always a problem.
Strength and limitations
Adverse effects were self reported, the register is observational.
Nevertheless, our register offered insight into the adverse effects of LEV.
Abstract
•Objectives To ascertain the frequency of self-reported anger and depression in Levetiracetam (LEV).
Design We compared patients with epilepsy (PWE) taking LEV with PWE taking other
Anti Epileptic Drugs (AED).
Setting All PWE and controls submitted information to the UK AED register.
Participants
We analyzed the data of 418 PWE and 41 control subjects. One hundred fifty eight took LEV in monotherapy or as part of polypharmacotherapy, 260 PWE took other AED. LEV and 45% on AED other than LEV reported depression as sometimes or always being a problem (p=0.584). Seven percent of control subjects reported anger as sometimes being a problem, 93% reported anger as never or rarely being a problem. Depression was never a problem in 75% of controls and rarely a problem in 25%.
Primary and secondary outcome measures All PWE and controls completed the
Conclusions
Anger and depression were more frequently reported as a problem by PWE than by control subjects. Our observational register of self-reported symptoms suggested anger being more often a problem in patients taking LEV than in PWE taking other AED.
Keywords: Epilepsy, Levetiracetam, adverse effects. irritability, anger, agitation, aggressive behavior and depression. [1] [2] [3] [4] It has been estimated on the basis of collective evidence that 12-15% of all patients will suffer psychiatric side effects 1 but compared to our clinical experience this seemed low. Feelings of anger seemed to be a particular problem, but were often only reported on direct questioning because the patients were embarrassed. The aim of our study was to find out how many patients with epilepsy (PWE) on LEV were suffering from anger. Because doctors may under-report adverse effects 5 we obtained the information directly from the patients using a self-referral register.
Methods
The UK AED Register is a prospective register to study the efficacy and adverse effects of AED. The register was established at The Walton Centre for Neurology and Neurosurgery, Liverpool in July 2008. Anybody who takes AED can self-refer to the register. The register is independent from the pharmaceutical industry. The register has rarely a problem; 3, sometimes a problem; and 4, always or often a problem. 6 The complete dataset is available on request.
We also collected age, gender, epileptic syndrome, severity of epilepsy, number of seizures in the last 4 weeks and other health problems, AED and other medication. We calculated the frequency of aggression occurring sometimes or always in patients on LEV and patients on other AED, and applied the chi squared test to test for associations of aggression with LEV. We did the same for the item depression. 
Results
Discussion
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